⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1389077 | 0.65 | — | — | |
| SCHEMBL22576622 | 0.61 | — | — | |
| SCHEMBL20433304 | 0.60 | — | — | |
| SCHEMBL8006674 | 0.60 | — | — | |
| SCHEMBL25241013 | 0.57 | — | — | |
| SCHEMBL2182519 | 0.54 | — | — | |
| Ethylene SCHEMBL2038444 | 0.54 | LMNA (0.47) | — | |
| Ethylene SCHEMBL76403 | 0.54 | LMNA (0.47) | — | |
| Ethylene SCHEMBL11150398 | 0.54 | LMNA (0.47) | — | |
| SCHEMBL175612 | 0.51 | CASP1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2712315-B1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE DISORDERS | ORYZON GENOMICS SA (ES) | 2021-11-24 | — | — | EP | disclosed |
| US-9908859-B2 | Lysine demethylase inhibitors for myeloproliferative disorders | ORYZON GENOMICS, S.A. (ES) | 2018-03-06 | — | — | US | disclosed |
| US-9790196-B2 | Lysine demethylase inhibitors for diseases and disorders associated with Flaviviridae | ORYZON GENOMICS S.A. (ES) | 2017-10-17 | — | — | US | disclosed |
| US-20170209432-A1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISEASES OR DISORDERS | ORYZON GENOMICS SA (ES) | 2017-07-27 | — | — | US | disclosed |
| US-20160081947-A1 | SELECTIVE LSD1 AND DUAL LSD1/MAO-B INHIBITORS FOR MODULATING DISEASES ASSOCIATED WITH ALTERATIONS IN PROTEIN CONFORMATION | ORYZON GENOMICS S.A. (ES) | 2016-03-24 | — | — | US | disclosed |
| US-20150232436-A1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE DISORDERS | ORYZON GENOMICS S.A. (ES) | 2015-08-20 | — | — | US | disclosed |
| US-20140329833-A1 | LYSINE DEMETHYLASE INHIBITORS FOR INFLAMMATORY DISEASES OR CONDITIONS | ORYZON GENOMICS, S.A (ES) | 2014-11-06 | — | — | US | disclosed |
| US-20140296255-A1 | LYSINE DEMETHYLASE INHIBITORS FOR THROMBOSIS AND CARDIOVASCULAR DISEASES | ORYZONG GENOMICS, S.A. (ES) | 2014-10-02 | — | — | US | disclosed |
| US-20140256742-A1 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH FLAVIVIRIDAE | ORYZON GENOMICS S.A. (ES) | 2014-09-11 | — | — | US | disclosed |
| US-20140163041-A1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISEASES OR DISORDERS | ORYZON GENOMICS S.A. (ES) | 2014-06-12 | — | — | US | disclosed |
| US-20130303545-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| WO-2012107499-A1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISEASES OR DISORDERS | ORYZON GENOMICS S.A. (ES) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012072713-A2 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH FLAVIVIRIDAE | ORYZON GENOMICS, S.A. (ES) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012042042-A1 | SELECTIVE LSD1 AND DUAL LSD1/MAO-B INHIBITORS FOR MODULATING DISEASES ASSOCIATED WITH ALTERATIONS IN PROTEIN CONFORMATION | ORYZON GENOMICS S.A. (ES) | 2012-04-05 | — | — | WO | disclosed |